BACKGROUND: Transfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high-quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients. STUDY DESIGN AND METHODS: A 31-question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures. RESULTS: We analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures. CONCLUSIONS: This survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence-based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.
BACKGROUND: Transfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high-quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat ALpatients. STUDY DESIGN AND METHODS: A 31-question survey queried providers caring for ALpatients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures. RESULTS: We analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures. CONCLUSIONS: This survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence-based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.
Authors: Jeffrey L Carson; Michael L Terrin; Helaine Noveck; David W Sanders; Bernard R Chaitman; George G Rhoads; George Nemo; Karen Dragert; Lauren Beaupre; Kevin Hildebrand; William Macaulay; Courtland Lewis; Donald Richard Cook; Gwendolyn Dobbin; Khwaja J Zakriya; Fred S Apple; Rebecca A Horney; Jay Magaziner Journal: N Engl J Med Date: 2011-12-14 Impact factor: 91.245
Authors: Ambuj Kumar; Rahul Mhaskar; Brenda J Grossman; Richard M Kaufman; Aaron A R Tobian; Steven Kleinman; Terry Gernsheimer; Alan T Tinmouth; Benjamin Djulbegovic Journal: Transfusion Date: 2014-11-12 Impact factor: 3.157
Authors: Hannes Wandt; Kerstin Schaefer-Eckart; Knut Wendelin; Bettina Pilz; Martin Wilhelm; Markus Thalheimer; Ulrich Mahlknecht; Anthony Ho; Markus Schaich; Michael Kramer; Martin Kaufmann; Lothar Leimer; Rainer Schwerdtfeger; Roland Conradi; Gottfried Dölken; Anne Klenner; Mathias Hänel; Regina Herbst; Christian Junghanss; Gerhard Ehninger Journal: Lancet Date: 2012-08-08 Impact factor: 79.321
Authors: P Rebulla; G Finazzi; F Marangoni; G Avvisati; L Gugliotta; G Tognoni; T Barbui; F Mandelli; G Sirchia Journal: N Engl J Med Date: 1997-12-25 Impact factor: 91.245
Authors: Gavin J Murphy; Katie Pike; Chris A Rogers; Sarah Wordsworth; Elizabeth A Stokes; Gianni D Angelini; Barnaby C Reeves Journal: N Engl J Med Date: 2015-03-12 Impact factor: 91.245
Authors: Càndid Villanueva; Alan Colomo; Alba Bosch; Mar Concepción; Virginia Hernandez-Gea; Carles Aracil; Isabel Graupera; María Poca; Cristina Alvarez-Urturi; Jordi Gordillo; Carlos Guarner-Argente; Miquel Santaló; Eduardo Muñiz; Carlos Guarner Journal: N Engl J Med Date: 2013-01-03 Impact factor: 91.245
Authors: Matthew A Warner; Nilesh S Jambhekar; Salwa Saadeh; Eapen K Jacob; Justin D Kreuter; William C Mundell; Alberto Marquez; Andrew A Higgins; Nageswar R Madde; William J Hogan; Daryl J Kor Journal: Transfusion Date: 2019-06-20 Impact factor: 3.157
Authors: Elizabeth St Lezin; Matthew S Karafin; Roberta Bruhn; Dhuly Chowdhury; Lirong Qu; Walter Bialkowski; Scott Merenda; Pamela D'Andrea; Anne-Lyne McCalla; Lisa Anderson; Sheila M Keating; Mars Stone; Edward L Snyder; Donald Brambilla; Edward L Murphy; Philip J Norris; Joan F Hilton; Bryan R Spencer; Steven Kleinman; Jeffrey L Carson Journal: Transfusion Date: 2019-03-18 Impact factor: 3.157
Authors: Matthew S Karafin; Roberta Bruhn; Matt Westlake; Marian T Sullivan; Walter Bialkowski; Gustaf Edgren; Nareg H Roubinian; Ronald G Hauser; Daryl J Kor; Debra Fleischmann; Jerome L Gottschall; Edward L Murphy; Darrell J Triulzi Journal: Transfusion Date: 2017-10-24 Impact factor: 3.157